Myriad Genetics

MYGNPhase 3

Myriad Genetics is a pioneer in genetic testing, having discovered the BRCA1/2 genes and launched the first commercial hereditary cancer risk test. With over 30 years of experience, the company now performs over 1 million genetic tests annually and serves more than 51,000 active ordering physicians. Myriad's mission is to advance health and well-being for all by providing clear, actionable genetic insights that empower personalized healthcare decisions.

Market Cap

$428.3M

Employees

~2,700

Focus

Diagnostics

MYGN · Stock Price

USD 4.5820.76 (-81.93%)

Historical price data

AI Company Overview

Technology Platform

Integrated platform for germline genetic testing, tumor genomic profiling, and pharmacogenomics, supported by one of the largest comparative genetic databases covering all ancestries to deliver actionable clinical reports.

Pipeline Snapshot

10 drugs in pipeline, 3 in Phase 3

Drug	Indication	Stage
Niraparib + Placebo	Ovarian Neoplasms	Phase 3
Rucaparib + Placebo	Ovarian Cancer	Phase 3
Active comparator: Niraparib + placebo	Ovarian Neoplasms	Phase 3
Niraparib	Ovarian Neoplasms	Phase 2
Oral rucaparib	Ovarian Cancer	Phase 2

Opportunities

Growth opportunities include expanding insurance coverage and patient access, leveraging its large genetic database for new test development, and capitalizing on the growing demand for integrated germline and tumor testing in oncology.

The focus on health equity and inclusive testing also opens new markets.

Risk Factors

Key risks include changes in insurance reimbursement policies, intense competition from other diagnostic firms, rapid technological obsolescence, and the challenges of integrating new leadership.

Regulatory scrutiny of genetic data privacy is also an ongoing concern.

Competitive Landscape

Myriad faces competition from large diagnostic firms like Labcorp and Quest, specialized genetic testing companies like Invitae and Natera, and oncology-focused players like Foundation Medicine and Guardant Health. Its differentiation lies in its comprehensive portfolio across five health areas, strong clinical heritage, and focus on actionable reporting.

Publications

Patents

Pipeline